Being on an antiretroviral treatment (ART) regimen of tenofovir disoproxil fumarate/emtricitabine may lower the risk of HIV-positive individuals contracting coronavirus disease 2019 (COVID-19).
HIV-positive individuals living in Spain, who were on antiretroviral treatment (ART) with the nucleotide reverse transcriptase inhibitor (NRTI) backbone of tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) appear to have a greater ability to fight off comorbid coronavirus disease 2019 (COVID-19), according to study results published in Annals of Internal Medicine.
Among the European countries, Spain has the highest prevalence of HIV, at 150,000 children and adults, reported UNAIDS, a current situation that overlaps with the COVID-19 pandemic. However, because the relationship between HIV and COVID-19 remains vague at best, the authors took up their investigation.
The authors of this cohort study of 77,590 persons—65% of all patients on ART in Spain—with HIV receiving care at any of 60 Spanish hospitals between February 1 and April 15, 2020, extracted data on those with cases of COVID-19 confirmed by polymerase chain reaction (PCR), most of whom had suppressed their HIV viral loads. Data on each HIV case (ie, age, sex, ART regimen), meanwhile, were extracted from the 2019 National HIV Hospital Survey. For comparison, the national COVID-19 Health Information System was used for data on the general population.
Seventy-five—day risk for the following were investigated:
Of the total patient cohort, just 0.3% (236) had PCR-diagnosed COVID-19. And among this group, 64% (151) required hospitalization, 6.4% (15) needed ICU care, and 8.5% (20) died. However, the median (interquartile range [IQR]) was just 7 (IQR, 4-10) days.
Stratifying for age and sex showed that being male and older than 70 increased both the chances of a COVID-19 diagnosis and hospitalization for it. In fact, more than 80% of new HIV diagnoses in the country are among men who have sex with men.
Most patients were on an ART regimen comprising a TAF/FTC backbone (33%), an ABC/3TC backbone (26%), or TDF/FTC (16%). The other regiments consisted of integrase inhibitors (50%), nonnucleoside reverse transcriptase inhibitors (21%), and protease inhibitors (19%), all as the third drug.
Additional results showed that persons with HIV taking ART with TDF/FTC had the lowest risk for a COVID-19—related hospitalization, at 10.5 (95% CI, 5.6-17.9), followed by 20.0 (95% CI, 14.2-27.3) for those receiving “other” regimens, 20.3 (95% CI, 15.2-26.7) for TAF/FTC, and 23.4 (95% CI, 17.2-31.1) for ABC/3TC.
However, the risks for an actual COVID-19 diagnosis differed except for TDF/FTC, which again had the lowest associated risk at 16.9 (95% CI, 10.5-25.9), followed by ABC/3TC at 28.3 (95% CI, 21.5-36.7), other regimens at 29.7 (95% CI, 22.6-38.4), and TAF/FTC at 39.1 (95% CI, 31.8-47.6)
Compared with the general population, this risk for COVID-19 diagnosis was lower among persons with HIV: 30.0 vs 41.7 per 10,000 persons. This even after accounting for health care workers among the general population, which still showed a greater risk for COVID-19 of 33.0.
Most importantly, TDF/FTC did not lead to any ICU admissions or death.
The authors proposed that the low risk of death and hospitalization for HIV-positive patients on NRTI regimens comes from “molecular docking and extension reactions with RNA-dependent RNA polymerase (RNAdRNAp).” Essentially, NRTIs may be effective at fighting COVID-19 because they inhibit RNAdRNAp. In particular, the small size of tenofovir diphosphate, which is the common active triphosphate form of TAF or TDF, has been cited because it “fits better in the active site of SARS-CoV-2 RNAdRNAp.”
“We took advantage of the overlap between 2 ongoing pandemics (HIV and SARS-CoV-2) in Spain,” the investigators concluded. “Our results suggest that the risk for COVID-19 diagnosis is not higher in HIV-positive persons than in the general population, and that HIV-positive patients receiving TDF/FTC had a lower risk for COVID-19 and related hospitalization than other HIV-positive persons.”
They suggested including current ART regimens as an area of focus both in studies of preexposure prophylaxis, as well as persons without HIV.
del Amo J, Polo R, Moreno S, et al. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy. Ann Intern Med. Published online June 26, 2020. doi:10.7326/M20-3689